Paris, January 8th 2014 -- Anaconda Pharma has received very positive feedback on the publication of its phase IIa study results for its lead compound AP611074. AP611074 is a candidate for the curative treatment of condyloma and the first inhibitor of Human Papillomavirus with clinical proof of concept. Anaconda Pharma is a Paris based biotech company whose scientific cofounders are affiliated with Institut Pasteur (Paris, France) and UC Berkeley (USA).
“As a result of the presentation of our successful Phase IIa study at Eurogin 2013 in Florence (Italy), and at the Congreso Latinoamericano de Patologia del Tracto Genital inferior y Colposcopia in Buenos Aires (Argentina), our company has drawn significant interest from fellow scientists and clinicians” stated Anaconda’s CEO, Dr. Marta Blumenfeld. “Condyloma presents a large unmet medical need, with millions of patients affected and no curative treatment available. After decades of effort, the scientific community was close to abandoning the idea of a treatment specific to the underlying virus, HPV subtypes 6/11. And as such many attending scientist viewed our results as an excellent surprise”.
Anaconda’s double-blind, placebo-controlled, phase IIa randomized clinical trial showed that AP611074 is safe and effective in removing or reducing ano-genital warts when applied as a topical gel over 6 weeks of treatment. The study demonstrated that AP611074 has an excellent safety profile resulting in high patient compliance, no patient drop-outs or treatment interruptions - in stark contrast to clinical trial data published for existing drug treatments. The “excellent safety profile” was lauded by leading clinicians in the field.
“Condyloma is one of the world’s most frequent sexually transmitted diseases with millions of new cases each year. Condyloma is mostly perceived by affected individuals as a disfiguring and shameful condition, causing anxiety and severe social and psychological stress. Unfortunately there is so far no satisfactory treatment available. AP611074, which prevents the replication of the virus in infected cells, is the first compound in clinical development that has the potential to meet the substantial medical need of patients impacted by Condyloma” commented Prof. Silvio Tatti, M.D., Ph.D., President of IFCPC (International Federation of Cervical Pathology and Colposcopy), Immediate Past Chairman Advisory Group Cervical Cancer Initiative, UICC (Union for International Cancer Control), Director Screening Program Cervical Cancer Unit at Hospital de Clinicas, University of Buenos Aires, Argentina, and Principal Investigator of the Phase IIa clinical study.
Responding to the significant interest from the scientific community Anaconda plans further presentations of its data at a number of other important scientific conferences, including: 1st South-American HPV meeting HPV Chile 2014, March 31st- April 2nd 2014, in Santiago, Chile; AOGIN 2014, April 25th- 27th 2014 in Beijing, China; 15th World Congress IFCPC, May 26th- 30th 2014 in London, UK; and the 29th International Papillomavirus Conference August 21st - 25th 2014 in Seattle, USA.
About condyloma
Ano-genital warts affect several million patients each year: global prevalence in the sexually active population amounts to about 1% (higher in emerging markets). While not life-threatening or debilitating, condyloma is mostly perceived by affected individuals as a disfiguring and shameful condition, causing anxiety and severe social and psychological stress. In most cases, patients experience early onset (adolescence/young adults) and frequent relapses during their entire life. Immunosuppressed persons (HIV patients, post-transplantation patients) frequently suffer from condyloma.
About Anaconda Pharma
Anaconda Pharma is focused on the development of treatments against infections by Human Papillomavirus (HPV). Anaconda’s scientific co-founders are affiliated with Institut Pasteur (Paris, France) and UC Berkeley (USA) and include some of the leading scientists in the field of HPV and related diseases. www.anacondapharma.com.
Please find attached the pdf version of the media release.
Anaconda Pharma Contact
Marta Blumenfeld
President and CEO
Villejuif Biopark
1 mail du Prof. Georges Mathé
94800 Villejuif
France
Tel+33(0)1 82 28 73 02
mblumenfeld@anacondapharma.com www.irfcom.ch
www.anacondapharma.com
Anaconda Pharma Media Contact
IRF Communications
Daniel Piller, Partner
Rämistrasse 4
8024 Zürich
Switzerland
Tel +41 43 244 81 54
daniel.piller@irfcom.ch
Help employers find you! Check out all the jobs and post your resume.
